Intervention not reported
Diastolic BP ‐ Aliskiren 300 mg vs placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Diastolic BP ‐ Aliskiren 600 mg vs placebo · primary hypertension
1 finding from 1 review
Intervention not reported
Diarrhoea ‐ Aliskiren 600 mg vs placebo · primary hypertension
The intervention may leads to higher diarrhoea ‐ Aliskiren 600 mg vs placebo (low certainty).
1 finding from 1 review
All‐cause mortality · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
Antihypertensive drug therapy showed no clear difference in all‐cause mortality compared with control (low certainty).
1 finding from 1 review
Cardiovascular mortality and morbidity Mean duration of 3.7 years · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
Antihypertensive drug therapy may leads to lower total cardiovascular mortality + morbidity compared with control (low certainty).
1 finding from 1 review
Cerebrovascular mortality + morbidity · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
Antihypertensive drug therapy may leads to lower cerebrovascular mortality + morbidity compared with control (low certainty).
1 finding from 1 review
Coronary heart disease mortality + morbidity · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
Antihypertensive drug therapy showed no clear difference in coronary heart disease mortality + morbidity compared with control (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
It is very uncertain whether antihypertensive drug therapy changes withdrawal due to adverse events compared with control (very low certainty).
1 finding from 1 review
Decrease in SBP5 at end of 1 year · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
1 finding from 1 review
Decrease in DBP6 at end of 1 year · adults aged 18‐59 years with primary hypertension (mild to moderate systolic or diastolic hypertension)
1 finding from 1 review
Intervention not reported
Systolic blood pressure clinical digital sphygmomanometer · adults with or without hypertension
1 finding from 1 review
Intervention not reported
Diastolic blood pressure clinical digital sphygmomanometer · adults with or without hypertension
1 finding from 1 review
Intervention not reported
Withdrawals due to adverse effects · adults with or without hypertension
1 finding from 1 review
Intervention not reported
Effect on systolic blood pressure (mean difference in systolic blood pressure) · adults with primary hypertension
The intervention showed no clear difference in effect on systolic blood pressure (mean difference in systolic blood… (moderate certainty).
1 finding from 1 review
Intervention not reported
Effect on diastolic blood pressure (mean difference in diastolic blood pressure) · adults with primary hypertension
The intervention showed no clear difference in effect on diastolic blood pressure (mean difference in diastolic… (moderate certainty).
1 finding from 1 review
Intervention not reported
Any adverse event · adults with primary hypertension
The intervention showed no clear difference in any adverse event (low certainty).
1 finding from 1 review
Intervention not reported
Adverse event leading to withdrawal · adults with primary hypertension
The intervention showed no clear difference in adverse event leading to withdrawal (low certainty).
1 finding from 1 review
All‐cause mortality · older adults with primary hypertension
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in all‐cause mortality compared with lower BP target (< 140/90 mmHg) (low certainty).
1 finding from 1 review
Stroke · older adults with primary hypertension
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in stroke compared with lower BP target (< 140/90 mmHg) (low certainty).
1 finding from 1 review
Serious adverse events: cardiovascular events · older adults with primary hypertension
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in cardiovascular serious adverse events compared with lower BP target (< 140/90 mmHg) (low certainty).
1 finding from 1 review